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ABSTRACT
Introduction: Ivermectin 1% cream (IVM 1%)
is indicated for the treatment of inflammatory
lesions of rosacea. The objective of this subanalysis
was to compare IVM 1% vs. metronidazole 0.75%
cream (MTZ 0.75%) in the treatment of
severe inflammatory lesions of rosacea.
Methods: A subanalysis of the
investigator-assessed severe subjects from a
Phase 3, investigator-blinded, randomized
study comparing IVM 1% once daily (QD)
with MTZ 0.75% twice daily (BID) over
16 weeks followed by a 36-week extension
period was performed. Efficacy assessments
were Dermatology Life Quality Index (DLQI)
and EuroQol-5 Dimension (EQ-5D)
questionnaires, investigator’s global
assessment (IGA), subject assessment of
rosacea improvement, and inflammatory
lesion counts. Adverse events (AEs) were
monitored throughout the study.
Results: A total of 161 subjects (16.7% of
overall study population; 80 IVM 1% and 81
MTZ 0.75%) had an IGA score of 4 at baseline
representing severe papulopustular rosacea.
Significantly more IVM 1% subjects had a
minimal clinically important difference
(MCID, defined as a decrease from baseline of
C4 points) in DLQI score than MTZ 0.75%
subjects at week 16 (65.4% vs. 39.2%;
P = 0.001) and week 52 (68.8% vs. 40.4%;
P = 0.003). At week 16, the mean EQ-5D score
for the IVM 1% subjects was higher (better
quality of life) than for MTZ 0.75% subjects
(0.941 vs. 0.896). Significantly more IVM 1%
subjects were IGA ‘‘clear’’ or ‘‘almost clear’’ at
week 16 compared to MTZ 0.75% (82.5% vs.
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63.0%; P = 0.005). Incidence of AEs was
comparable between groups.
Conclusion: Better efficacy with IVM 1% cream
(QD) compared to MTZ 0.75% cream (BID)
contributes to an improved quality of life with
significantly more patients achieving an MCID
in DLQI score at week 16 and higher mean
EQ-5D score. IVM 1% cream is thus a better
alternative than MTZ 0.75% cream for severe
papulopustular rosacea patients.
Trial registration: EUDRACT number:
2011-004791-11.
Funding: Galderma R&D.
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INTRODUCTION
Rosacea is a chronic inflammatory disease that
affects around 10% of the population in Europe
[1]. Clinical characteristics include primary
features (transient erythema or flushing, fixed/
non-transient erythema, inflammatory
papules/pustules, telangiectasia) and secondary
features (burning, plaque, edema) in various
combinations [2]. As it is readily visible on the
face, rosacea has a considerable impact on a
patient’s quality of life (QoL) [3].
Until recently, patients with severe
inflammatory lesions were often treated with
antibiotics. However, a European Commission
action plan [4] and World Health Organization
global action plan [5] have been implemented in
recent years to tackle the ever-increasing problem
of antimicrobial resistance, including reducing
antibiotic use in non-infectious diseases.
Current topical treatments for inflammatory
lesions of rosacea (papulopustular) include
metronidazole 0.75% and 1% topical
formulations and azelaic acid 15% gel [6].
Topical ivermectin 1% cream (IVM 1%;
Soolantra 1% cream, Galderma, Lausanne,
Switzerland) was approved across Europe in
2015 based on 2 pivotal Phase 3 studies [7]
and 1 supportive Phase 3 study [8], involving a
total of over 2300 subjects. In the 16-week
active-controlled study in subjects
with moderate-to-severe papulopustular
inflammatory lesions of rosacea, once daily
(QD) IVM 1% was shown to be superior to
twice daily (BID) metronidazole 0.75% cream
(MTZ 0.75%) in reducing inflammatory lesion
counts [8]. IVM 1% demonstrated early onset of
efficacy, improved efficacy and longer remission
over an existing reference treatment [8, 9],
making it a new therapeutic option that meets
the needs of rosacea patients.
The objective of this post hoc subanalysis
was to compare IVM 1% cream (QD) with MTZ
0.75% cream (BID) in the treatment of subjects
with investigator-assessed severe inflammatory
lesions of rosacea (papulopustular).
METHODS
Study Design and Subjects
This was a post hoc subanalysis of a Phase 3,
investigator-blinded, randomized, parallel-group,
superiority study that previously compared the
efficacy and safety of QD IVM 1% cream with BID
MTZ 0.75% cream in subjects with
moderate-to-severe papulopustular rosacea. The
study included a 16-week treatment period
(Part A) [8] followed by a 36-week extension
period to assess relapse among the successfully
treated patients (Part B) [9] for a total study period
of 52 weeks. The study design has previously been
described in detail [8].
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This post hoc subgroup analysis was
performed on study subjects with severe
papulopustular rosacea, i.e., an investigator’s
global assessment (IGA) score (see Table 1) of 4
at baseline.
Treatment
As previously described, subjects were
randomized in a 1:1 ratio to receive either
IVM 1% (QD) or MTZ 0.75% (BID) for
16 weeks. Study treatment, IVM 1% or MTZ
0.75%, was discontinued at the end of the
16-week treatment period and was restarted in
the 36-week extension period in the event of
relapse (IGA score of at least 2) with treatment
being stopped when the IGA score returned to 0
or 1 (multiple retreatment periods were
allowed). Study drugs were to be applied in a
thin film on the entire face (right and left
cheeks, forehead, chin and nose), avoiding the
upper and lower eyelids, lips, eyes, and mouth.
Assessments
EuroQol-5 Dimension (EQ-5D) [10] and
Dermatology Life Quality Index (DLQI) [11] QoL
questionnaires were completed at baseline,
week 16, week 32, and week 52. Subjects
evaluated their rosacea improvement at week 16
and week 52. At each study visit, inflammatory
lesions (papules and pustules) were counted on
five facial regions (forehead, chin, nose, right
cheek, left cheek) and the subject’s rosacea was
graded according to the IGA scale (Table 1). AEs
were monitored throughout the study.
Statistical Methods
The means of the DLQI total score and EQ-5D
index were calculated using the definitions for
each questionnaire.
The EQ-5D descriptive system consists of five
dimensions (mobility, self-care, usual activities,
pain/discomfort and anxiety/depression) with
three levels each (no problems, some problems,
and extreme problems).The EQ-5D results were
converted into a single summary index (where
0 = dead and 1.0 = full health) by applying
Dutch preference weights [12]. An
improvement in the EQ-5D score of C0.074 vs.
baseline is considered as the minimal clinically
important difference (MCID) [13].
The 10 DLQI questions had four possible
responses from not at all (0) to very much (3)
[11] and the total score was calculated by
summing the score of each question; the
maximum score is 30 (extremely large effect
on patient’s life) and minimum is 0 (no effect
on patient’s life). The 10 questions cover 6
domains and DLQI subscale scores were
calculated for symptoms and feelings, daily
activities, leisure, work and school, personal
relationships, and treatment. The changes from
Table 1 Investigator’s global assessment (IGA) scale
Grade Score Clinical description
Clear 0 No inﬂammatory lesions present, no erythema
Almost clear 1 Very few small papules/pustules, very mild erythema present
Mild 2 Few small papules/pustules, mild erythema
Moderate 3 Several small or large papules/pustules, moderate erythema
Severe 4 Numerous small and/or large papules/pustules, severe erythema
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baseline were analyzed by analysis of
covariance, including baseline DLQI as a
covariate. A change in DLQI score of at least 4
points is considered MCID and suggests that
there has been a meaningful change in the
patient’s QoL since the previous DLQI
measurement [14].
Efficacy endpoints included success rate,
expressed as percentage of subjects with IGA
rated as 0 or 1 (analyzed by chi2 or Fisher’s exact
test), IGA and percent change in lesion counts
(analyzed using Wilcoxon rank sum test); other
variables were descriptively analyzed.
Analysis was performed using SAS version 9.2
(SAS Institute Inc., Cary, NC, USA).
Compliance with Ethics Guidelines
This article is based on a previously conducted
study and does not involve any new studies of
human or animal subjects performed by any of
the authors. Informed consent was received




Of the total of 962 randomized subjects (478
IVM 1%, 484 MTZ 0.75%), 161 (16.7%; 80 IVM
1%, 81 MTZ 0.75%) had an IGA score of 4 at
baseline representing severe inflammatory
lesions of rosacea.
Quality of Life
In this subgroup of 161 subjects with severe
inflammatory lesions of rosacea, the mean
DLQI total scores at baseline were 7.8 and 6.6
for the IVM 1% and MTZ 0.75% groups,
respectively, indicating a moderate impact of
severe papulopustular rosacea on QoL.
At week 16, a greater reduction from baseline
(i.e., a greater improvement in QoL) in the mean
DLQI score was observed for IVM 1% group
subjects than MTZ 0.75% subjects (-6.0 vs.-3.8;
P = 0.014). Similar results were observed at week
52 (-6.0 vs. -4.8; P = 0.010; Fig. 1).
After 16 weeks treatment, the proportion of
subjects with a DLQI score of 0 or 1 representing
no detrimental effect on QoL was 69.2% for the
IVM 1% group vs. 53.2% for the MTZ 0.75%
group (P = 0.03); at week 52 the difference
between the 2 groups was even higher at
81.3% vs. 61.7%, respectively (P = 0.022).
At week 16, significantly more IVM 1%
subjects had an MCID of the DLQI score than
MTZ 0.75% subjects (65.4% vs. 39.2%;
P = 0.001). A similar statistically significant
difference was observed at week 52 (68.8% vs.
40.4%, respectively; P = 0.003).
The greatest improvement in the mean score
between baseline and week 16 was observed for
the DLQI subscale of symptoms and feelings
with a mean score of -2.2 for the IVM 1% group
and -1.6 for the MTZ 0.75% group (P = 0.03).
Fig. 1 Mean change from baseline in DLQI score (a lower
score indicates better quality of life). The statistical test was
adjusted for the baseline values. BID twice daily, DLQI
Dermatology Life Quality Index, QD once daily
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At week 16, the mean EQ-5D score for the
subjects treated with IVM 1% was higher
(indicating a better QoL) than for subjects
treated with MTZ 0.75% (0.941 vs. 0.896) and
the mean change from baseline in EQ-5D score
was 0.074 vs. 0.069 (P = 0.032) for the IVM 1%
group and the MTZ 0.75% group, respectively
(Fig. 2). Similarly, at week 52, the mean change
from baseline was significantly higher for IVM
1% subjects than MTZ 0.75% subjects (0.103 vs.
0.084; P = 0.010). Subjects with IGA success
(grade 0–1) consistently had statistically
significantly better EQ-5D scores than subjects
with IGA failure (grade 2–4; 0.939 ± 0.131 vs.
0.870 ± 0.172; P\0.01).
The most improved EQ-5D dimensions were
pain/discomfort and anxiety/depression. The
number of subjects without pain/discomfort was
22.1% higher in the IVM 1% group at week 16
compared to baseline, whereas the respective
increase was only 5.9% in the MTZ 0.75% group.
Efficacy
For success rate based on an IGA score of 0 or 1
at week 16, more subjects in the IVM 1% group
(66/80 subjects, 82.5%) were assessed as success
compared to the MTZ 0.75% group (51/81
subjects, 63.0%), i.e., a between-group
difference of 19.5% (Fig. 3).
At week 16, twice as many IVM 1% subjects
(22/80 subjects, 27.5%) than MTZ 0.75%
subjects (10/81 subjects, 12.3%) had an IGA
score of 0 (clear; Fig. 3).
At week 16, the mean (median) percentage
reduction in inflammatory lesion counts from
baseline (intent-to-treat last observation carried
forward) was higher for the IVM 1% group at
Fig. 2 Mean change from baseline in EQ-5D score (a
higher score indicates better quality of life). The statistical
test was adjusted for the baseline values. EQ-5D EuroQol-5
Dimension
Fig. 3 Success rate based on subjects who achieved an IGA
score of 0 (clear) or 1 (almost clear) (intention-to-treat,
last observation carried forward). IGA investigator’s global
assessment, IVM ivermectin 1% cream,MTZ metronidazole
0.75% cream
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-85.1% (-93.7%) compared to the MTZ 0.75%
group at -75.2% (-88.1%) (P = 0.011).
Subjects’ rating of rosacea improvement is
illustrated in Fig. 4. Patient self-assessment of
rosacea improvement at week 16 was good/
excellent for 85.9% of IVM-treated subjects vs.
67.5% of MTZ-treated subjects. Similarly, at
week 52, 93.7% of subjects in the IVM 1%
group rated their improvement as good/
excellent compared to 77.5% in the MTZ
0.75% group.
The overall success rate, i.e., percentage of
subjects who were successfully treated over the
treatment period of 16 weeks (IGA 0 or 1) and
never relapsed during the 36-week extension
period, was higher in the IVM 1% group than
the MTZ 0.75% group (23.2% IVM 1% vs. 12.3%
MTZ 0.75%).
Safety
There were a total of three related adverse
events in Part A (rosacea in 1 IVM 1% subject;
allergic dermatitis in 1 MTZ 0.75% subject;
pruritus in 1 MTZ 0.75% subject) and two
related adverse events in Part B (pruritus and
rosacea in 1 IVM 1% subject).
DISCUSSION
The greater improvement in QoL in the IVM 1%
group than in the MTZ 0.75% group reflects the
superior efficacy with IVM 1% with a
comparable safety profile in this
subpopulation of patients with severe
inflammatory lesions of rosacea.
Although QoL is inherently subjective in
nature, the importance of patient-reported
outcomes in evaluating the efficacy and safety
of treatments for rosacea was highlighted in the
2015 Cochrane review with ‘‘Change in quality
of life’’ being a primary outcome measure [6]. It
is important to determine whether changes in
physical symptoms interpreted by the clinician
translate into measurably significant changes in
QoL for the individual. This was the case since
mean difference in DLQI scores and EQ-5D
scores were consistently statistically
significantly better for patients with treatment
success than for those with treatment failure.
Fig. 4 Subjects’ rating of rosacea improvement. IVM ivermectin 1% cream, MTZ metronidazole 0.75% cream
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Since the extent of improvement in QoL total
scores lack a direct clinical meaning, the
concept of MCID (defined previously [13, 14])
was used to confirm clinically relevant
treatment effectiveness.
More subjects in the IVM 1% group had an
MCID in DLQI score compared with the MTZ
0.75% group at week 16 (65.4% vs. 39.2%;
P = 0.001). As all patients who continued into
Part B had been treated successfully in Part A
whatever the treatment group (i.e., all were IGA
0 or 1 at week 16), it may be expected that the
subjects in both groups would be equally
satisfied with the treatment in Part B.
However, this was not the case since at week
52, the improvement in proportion of subjects
with an MCID in DLQI score (68.8% IVM 1% vs.
40.4% MTZ 0.75%; P = 0.003) was again
significantly greater in the IVM 1% group,
reflecting the clinical superiority of IVM 1%
over the long-term. These results were
corroborated with the results obtained using
the generic EQ-5D questionnaire, with which
the mean change from baseline at week 16 and
week 52 were significantly higher in the IVM
1% group than the MTZ 0.75% group. The
EQ-5D is a very widely used generic
questionnaire and it is unusual to observe a
statistically significant difference in scores for
dermatological diseases, especially with a small
sample size.
QoL data collected at week 32 could not be
directly compared between the IVM 1% and
MTZ 0.75% groups as the level of exposure to
the two drugs was heterogeneous at this time
point. In fact, more subjects in the MTZ 0.75%
group had already been re-treated at week 32
compared to the IVM 1% group due to the
longer remission time for the IVM 1% group, as
reported previously [9].
In this subanalysis of severe patients, the
success rate at week 16 was higher in the
IVM-treated group than in the MTZ-treated
group (82.5% vs. 63% IGA 0 or 1; P = 0.005).
The superiority of IVM 1% was more
pronounced in this subpopulation of severe
subjects (between-group difference of 19.5%)
than in the overall population of
moderate-to-severe subjects, in which the
success rate was reported to be 84.9% IVM 1%
vs. 75.4% MTZ 0.75% at week 16 (P\0.001;
between-group difference of 9.5%) [8].
Archive photographs are shown in Fig. 5 to
illustrate a severe subject (IGA of 4 at baseline)
who had an IGA of 1 after 14 weeks treatment
Fig. 5 Photographs of a severe subject with a an IGA of 4
before treatment and b an IGA of 1 after 14 weeks
treatment with ivermectin 1% cream once daily. IGA
investigator’s global assessment. Informed consent was
received from the patient for publication of these
photographs
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with IVM 1% cream QD. As the IGA is a
composite score including both inflammatory
lesions and erythema, it is difficult to obtain a
score of 0 (clear) since a combination treatment
may be required. Of the successfully treated
subjects (IGA score of 0 or 1), the proportion of
severe subjects with complete healing of both
inflammatory lesions and erythema lesions (an
IGA score of 0) at week 16 was 27.5% in the IVM
1% group compared to 12.3% in the MTZ 0.75%
group. The difference between an IGA score of 0
and 1 is clinically relevant to the patients since
they want a full reduction of lesions and
erythema.
The significantly greater reduction in lesion
count at week 16 in the IVM 1% group (-85.1%
vs. -75.2% for MTZ 0.75%; P = 0.011)
translated into a clinically meaningful
difference for the investigator (reduction in
IGA score) and for the subject since more
subjects in the IVM 1% group (85.9%) rated
the improvement in their rosacea as good or
excellent at week 16 compared to the MTZ
0.75% group (67.5%).
At week 52, the overall success rate of
subjects who never relapsed was higher in the
IVM 1% group than the MTZ 0.75% group
(23.2% IVM 1% vs. 12.3% MTZ 0.75%), which is
important from a pharmacoeconomic
perspective, in addition to the fact that IVM
1% is QD and so requires a lower quantity of
product per treatment compared to MTZ 0.75%
(BID).
Comparable safety results demonstrated that
both products were very well tolerated, which is
important as rosacea patients tend to have
highly sensitive skin. The results in this group
of severe subjects are consistent with a previous
long-term safety study on IVM 1% cream in
moderate-to-severe subjects [15].
Severe inflammatory lesions of rosacea are
often treated with oral antibiotics, particularly
tetracyclines, despite a poor safety profile
[6, 16]. However, antibiotic resistance is now a
major threat to public health causing people to
be sick for longer and increasing the cost of
health care with lengthier stays in hospital [5].
Dermatologists contribute to overall antibiotic
use and tend to prescribe antibiotics
chronically, particularly for acne and rosacea
[17]. Hence, there is a need to find effective
alternatives to antibiotics or sub-anti–microbial
dosage forms. One such example is the use of a
sub-anti–microbial dosage of doxycycline
(40 mg modified-release doxycycline), which
has anti-inflammatory rather than
anti-microbial effect, that has been reported to
be as effective as 100 mg with significantly
fewer gastrointestinal side effects [18]. Since
ivermectin is a member of the avermectin class
of compounds (with anti-inflammatory and
anti-parasitic effects) and is not an antibiotic,
it is thus an effective alternative treatment for
papulopustular rosacea, even in severe patients.
Limitations of this subanalysis include the
small number of subjects. However, despite the
small sample size, statistical significance was
reached for the efficacy endpoints. Another
limitation was the absence of double-blind due
to the fact that IVM 1% is QD, whereas MTZ
0.75% is BID, as well as the obvious difference
in appearance of the two creams. However, a
QD treatment has the advantage of being more
appealing to patients, especially when it is more
efficacious.
CONCLUSIONS
In patients with severe papulopustular rosacea,
better efficacy with IVM 1% cream compared to
MTZ 0.75% cream contributes to an improved
QoL with significantly more patients achieving
an MCID in DLQI score and higher mean EQ-5D
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score. IVM 1% cream QD is thus a better
alternative than MTZ 0.75% cream BID for
severe papulopustular rosacea patients.
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